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Sudden cardiac death (SCD) is a major cause
of premature death in young adults and children
in developed countries. Standard forensic autopsy
procedures are often unsuccessful in determining
the cause of SCD. Post-mortem genetic testing,
also called molecular autopsy, has revealed that a
non-negligible number of these deaths are a re-
sult of inherited cardiac diseases, including ar-
rhythmic disorders such as congenital long QT
syndrome and Brugada syndrome. Due to the
heritability of these diseases, the potential impli-
cations for living relatives must be taken into con-
sideration. Advanced diagnostic analyses, genetic
counselling, and interdisciplinary collaboration
should be integral parts of clinical and forensic
practice. In this article we present a multidiscipli-
nary collaboration established in Lausanne, with
the goal of properly informing families of these
pathologies and their implications for surviving
family members. In Switzerland, as in many other
countries, legal guidelines for genetic testing do
not address the use of molecular tools for post-
mortem genetic analyses in forensic practice. In
this article we present the standard practice
guidelines established by our multidisciplinary
team.
Key words: sudden cardiac death; molecular au-
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Summary
Cardiovascular disease is one of the leading
causes of death in developed countries [1–3]. The
Swiss Federal Statistical Office ranked cardiovas-
cular disease as the number one cause of death in
men and women in Switzerland. Although the
majority of cardiac death victims are elderly, many
children and young adults under the age of 35 die
each year due to various cardiac pathologies.
Many of these premature cardiac deaths are sud-
den and unforeseen. Recent progress in the fields
of molecular biology and human genetics have
enabled identification of the genetic aetiology of
many cardiac diseases, including multiple causes of
sudden cardiac death (SCD) [4, 5]. Some of the ge-
netically determined cardiac diseases are charac-
terised by morphological changes observed at au-
topsy, e.g., hypertrophic cardiomyopathy (HCM)
or arrhythmogenic right ventricular cardiomy-
opathy (ARVC) [6, 7]. Cardiac diseases related to
arrhythmic syndromes, such as congenital long
QT syndrome (LQTS), Brugada syndrome and
catecholaminergic polymorphic ventricular
tachycardia (CPVT) can only be diagnosed after
genetic analysis at postmortem [4, 8]. Previous
studies have reported that genetically determined
cardiac disease is responsible for more than 50%
of SCD cases in children [9, 10]. Preventive treat-
ment exists for many of these diseases, thus iden-
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tifying other family members at risk, is very im-
portant. Postmortem evaluation is recommended
in all cases of SCD, not only to determine the un-
derlying cause of death, but to prevent future
ones in surviving family members. In some cases,
if an inherited arrhythmic syndrome is suspected,
the phenotype determination of first-degree rela-
tives may help to identify a channelopathy and
subsequent genetic analyses can be performed on
the index patient or family members.
General practitioners are particularly impli-
cated in the ethical issues surrounding the death
and autopsy of SCD victims since they are most
often in direct contact with family members. The
legal and ethical aspects of genetic analyses in
postmortem investigation are complex, especially
in a forensic context. This is a very important
problem in many countries. The detection and
follow-up of familial cases is challenging and re-
quires close collaboration between specialists
from different fields. The goal of this paper is to
present our experience with forensic autopsy and
genetic testing in cases of sudden cardiac death in
young individuals.
Causes of sudden cardiac death
The causes of SCD vary depending on the age
of the individuals affected. In individuals over 35
years, ischaemic cardiac disease is most common
[11]. Autopsy often reveals coronary artery occlu-
sion or a previously constituted infarct. In individ-
uals under 35 years, cardiomyopathies are ranked
above cardiac ischaemic disease, valvular disease
and conduction system pathology [12–15]. Sud-
den death in athletes is often due to undiagnosed
structural heart disease. The cause of sport SCD
also varies depending on the age of the athlete.
Atherosclerotic coronary artery disease remains
the most common cause of death in athletes aged
35 years or older; whereas in younger athletes a
broad range of cardiovascular causes, including
congenital and inherited disorders, have been
reported [16–18]. In some cases autopsy investi-
gation is unable to determine the cause of death,
despite being performed in accordance with inter-
national recommendations [19, 20]. Autopsy neg-
ative sudden deaths account for 6 to 40% of all
SCDs [12, 13, 15], which are currently considered
to be caused by sudden arrhythmic death syn-
dromes [4, 8].
Cardiac pathologies with a morphological substrate at autopsy
Hypertrophic cardiomyopathy (HCM)
Hypertrophic cardiomyopathy (HCM) is a
relatively common clinical condition (1 in 500 in-
dividuals) characterised by cardiac hypertrophy,
myocyte disarray and fibrosis. The clinical course
of HCM varies greatly, ranging from a chronically
managed condition to sudden death. Symptoms
frequently include chest pain, exertion-related
dyspnoea, syncope, and progressive exercise intol-
erance. HCM follows an autosomal dominant in-
heritance pattern and can be caused by mutations
in at least 24 genes encoding for sarcomeric, cal-
cium-handling, and metabolic regulatory proteins.
The diagnostic yield of genetic analyses in clinical
cases of familial HCM can reach up to 60%, but
requires testing by experienced centres [21].
Arrhythmogenic right ventricular cardio-
myopathy/dysplasia (ARVC/D)
ARVC/D is a familial cardiomyopathy that
may result in arrhythmias, heart failure and/or
sudden death. It is characterised by progressive
myocyte loss with fibro-fatty replacement, and has
a predilection for the right ventricle [22]. The
prevalence is estimated to be between 1 in 5000 to
1 in 10000 individuals. Most cases of ARVC/D
follow an autosomal dominant inheritance pattern
with variable penetrance and expressivity. To date,
eight susceptibility genes encoding different pro-
teins of the desmosome of cardiomyocytes and
three additional genetic loci have been identified
[5, 23–25].
Cardiac pathologies without a morphological substrate at autopsy
Congenital long QT syndrome (LQTS)
Congenital LQTS comprises a distinct group
of cardiac channelopathies characterised by de-
layed repolarisation of the myocardium reflected
by QT prolongation (QTc >450 ms in adult males,
>470 ms in adult females and >460 ms in individu-
als <15 yrs old), and an increased risk for syncope
and sudden death. Individuals with LQTS may or
may not manifest QT prolongation on a resting
12-lead surface electrocardiogram [26]. The heart
is structurally normal. The prevalence of LQTS
may be as high as 1 in 2500 individuals. LQTS is a
genetically heterogeneous disorder usually inher-
ited in an autosomal dominant mode. Autosomal
712-718 Michaud 12837.qxp 26.11.2009 14:19 Uhr Seite 713
714
Molecular autopsy in sudden cardiac death and its implication for families
dominant LQTS was previously known as Ro-
mano-Ward syndrome. Although rare, LQTS can
be also inherited as a recessive trait, as first de-
scribed by Jervell and Lange-Nielsen, and is char-
acterised by severe QT prolongation and sen-
sorineural hearing loss. Approximately 5–10% of
LQTS cases result from a spontaneous/sporadic
germline mutation. To date, several hundreds of
mutations have been identified in 12 genes, with
~75% of clinically robust LQTS due to mutations
in three genes. Loss-of-function mutations in
KCNQ1, which encodes I
Ks
potassium current,
cause LQT1 syndrome. Loss-of-function muta-
tions in KCNH2, encoding I
Kr
potassium current,
cause LQT2, while gain-of-function mutations in
SCN5A, encoding I
Na
sodium current, cause
LQT3. These three genes code for ion channel
subunits involved in the generation of the cardiac
action potential. According to published studies,
75% of patients with a LQTS phenotype are car-
riers of a specific genetic mutation. In absence of
family history or uncertain or “borderline” clini-
cal features according to clinical scoring methods,
there is a significant fall-off in the yield of genetic
testing to about 45% [5, 24, 27, 28].
Other rhythms disturbances related
to sudden death syndromes
Catecholaminergic polymorphic ventricular
tachycardia (CPVT) is a syndrome of exercise or
emotion-induced polymorphic ventricular tachy-
cardia or ventricular fibrillation in children and
young adults. It occurs in a structurally normal
heart. In approximately 30% of cases, the family
history reveals one or more premature sudden
deaths that usually occurred during childhood
[29, 30]. Mutations in the RyR2-encoded cardiac
ryanodine receptor/calcium release channel rep-
resent the most common genetic subtype of
CPVT.
Brugada syndrome, first described in 1992, is
widely recognised as a form of inherited sudden
cardiac arrest. This syndrome is characterised by a
specific ECG abnormality and an associated risk of
ventricular fibrillation and sudden death. Most of
the identified disease-causing mutations have been
located in the SCN5A gene, which encodes the a
subunit of the human cardiac voltage-gated
sodium channel. Such mutations, however, can
only be identified in approximately 30% of affected
individuals [24, 31, 32]. Several hundred SCN5A
mutations have been reported and the ones that
have been functionally tested lead to a loss-of-
function of the cardiac sodium channel [33].
Legal aspects
Legal aspects of postmortem genetic
testing in Europe
Recent advances in the fields of molecular
pathology and genetics have resulted in the ability
to test for many genetic mutations. In 2007 Borry
et al. [34] summarised the legal and ethical aspects
of genetic testing and counselling in different Eu-
ropean countries. At present there are no existing
guidelines for genetic testing in cases of sudden
cardiac death in forensic practice in Switzerland
or Europe. We recently conducted an interna-
tional survey, which demonstrated that autopsy
practice varies widely between countries and that
genetic postmortem testing is performed in only
a few academic centres. Responders affirmed that
it is very difficult to establish a link between the
autopsy of a sudden death victim and the cardio-
logical assessment of their family members. The
reasons for this difficulty are numerous, but are
largely related to the legal and ethical complexi-
ties of postmortem genetic testing.
Legal aspects of genetic testing
in Switzerland
The particularity of the judiciary in Switzer-
land is the coexistence of different laws at the na-
tional (federal) and local (cantonal) levels. In light
of the ethical and legal sensitivity of postmortem
genetic testing, physicians should have some basic
knowledge of the legal aspects involved. A new law
on genetic testing (LAGH, Loi fédérale Suisse sur
l’analyse génétique humaine) came into force in
2007. In addition to this law there is a larger legal
framework that regulates genetic testing, which in-
cludes federal laws concerning confidentiality,
abortion and data protection (LPD, Loi fédérale
sur la protection des données, Swiss federal data
protection law [19.6.1992], http://www.admin.ch/
ch/f/rs/235_1/), as well as different cantonal laws.
This larger framework, however, is broad in scope
and of uncertain application for genetic testing and
its numerous complexities [35].
A new federal law on human subject research
has been recently drafted. It has provoked signifi-
cant discussion regarding the regulation of re-
search, including genetic testing. The new federal
law is not to be expected before 2011. For the time
being article 20, al. 2, of the federal law on genetic
testing, details the guidelines that apply to genetic
research, stipulating that genetic analyses are al-
lowed within a research framework on material
that has been obtained for other non-research pur-
poses. The material must be anonymous and the
person from who the material stems (or its legal
representative if the person is incompetent) must
be informed of their rights and not express any op-
position to the use of their biological material.
Article 14 of the LAGH states that non-direc-
tive genetic counselling must take place before a
genetic test is performed, and 4 prohibits genetic
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discrimination in line with the principles of art. 119
of the Swiss Constitution. Employers are not al-
lowed to request presymptomatic genetic testing,
except if the tests are a valid and recognised means
of preventing work-related disease or accidents.
Moreover, the law aims to protect individuals who
carry morbid genes against discrimination by in-
surance companies.The latter are not permitted to
carry out or require presymptomatic or pre-natal
genetic testing before establishing an insurance
contract. The only exception refers to private non-
obligatory insurance where, in certain cases only,
insurance companies may ask clients to send a copy
of results from genetic testing previously per-
formed (LAGH, art. 27 et 28). Article 6 of the law
guarantees the individual right to decline informa-
tion related to one’s genetic patrimony.
The federal law on genetic testing (LAGH)
does not explicitly address the issue of post-
mortem genetic testing, leaving only the local
(cantonal) laws applicable for autopsy investiga-
tion (for example loi sur la santé publique vaudoise
and loi genevoise sur la santé du canton de Genève).
Legal aspect of genetic testing
after a forensic autopsy
The legal issues surrounding forensic autopsy
implicate both the prospective analyses of routine
cases and the retrospective analyses for research
purposes. The particularity of a forensic autopsy
is that the postmortem examination can be car-
ried out without the consent of the deceased or a
proxy. The legal guidelines were established after
multiple discussions with the lawyers from the
legal department of the hospital. The ethical as-
pects were discussed at length with the ethics
committee members. The investigating magis-
trate can mandate genetic testing on autopsy sam-
ples in order to determine the cause of death. Ret-
rospective analyses assimilated to a research activ-
ity necessitate consent of the individual prior to
death or proxy consent after death, as well as ap-
proval by the local ethics committee. In our prac-
tice only prospective testing is currently per-
formed.
Current multidisciplinary collaboration
Lausanne. Sudden death cases are selected on the
basis of presumed clinical history, scene investiga-
tion and autopsy findings. Cases with a negative
autopsy including histological, toxicological, clin-
ical chemistry and microbiological analyses are
presumed to be due to an arrhythmic syndrome.
Cases of sudden death in which the autopsy re-
veals a hypertrophic heart are considered as sus-
pect for hypertrophic cardiomyopathy (HCM),
even in the absence of typical histological pat-
terns. HCM has been reported as the cause of
SCD in children and athletes even in the absence
of the left ventricular hypertrophy, as the diagno-
sis is not always straightforward [36]. Evaluating
clinical histories of sudden death in forensic prac-
tice can prove very challenging. There is often a
blurred history ranging from the individual sim-
ply collapsing, to one in which the death takes
place in a much more complicated scenario. For
example, the sudden arrhythmic event caused by a
genetic disease can occur when a person is driving
or swimming, resulting in a traffic accident or
drowning [37]. The SCD may also be related to a
low-level intoxication by antidepressants or anti-
psychotics known to be linked to drug-induced
QT prolongation and the development of torsade
de pointes arrhythmias, or to a Brugada syndrome
phenotype and the development of polymorphic
ventricular arrhythmias [38–40]. Due to the com-
plexities of evaluating clinical histories, our selec-
tion sometimes includes some of the aforemen-
tioned cases. Once a case is selected, the forensic
pathologist informs the investigating magistrate
of the possibility of performing genetic analyses.
Magistrates are informed that the cause of death
Figure 1
Flow chart of genetic testing in SCD in forensic practice.
The genetic analyses in SCD may be performed during the forensic investigation only
with the permission of the investigating magistrate.The results of the genetic analyses
are transmitted to the investigating magistrate and with his permission to the family. If
family members are not contacted or decline to be informed, there is no follow-up.
SUDDEN
CARDIAC
DEATH
STOP
STOP
STOP
GENETIC
COUNSELLING
RESULTS OF
GENETIC
TESTING
YES
YES
YES
NO
NO
NO
FORENSIC
AUTOPSY
PERMISSION OF
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In Lausanne, the multidisciplinary collabora-
tion “Cardiogene” was established between the
departments of cardiology, medical genetics and
forensic medicine. Paediatric deaths are autopsied
in collaboration with the Institute of Pathology in
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may be directly or indirectly related to a geneti-
cally determined cardiac disease. They occasion-
ally question the cost and time involved in such
analyses. If a magistrate orders the genetic analy-
ses, the report of the forensic autopsy notes that
“the results of the genetic analyses will follow”.
With permission of the magistrate, the forensic
pathologist is then free to speak with family mem-
bers of the deceased and to encourage them to
seek genetic counselling.
The genetic analyses are performed in order
to detect any mutations described in arrhythmic
syndromes. In Lausanne, it is currently possible to
analyse the following genes implicated in arrhyth-
mic syndromes: SCN5A, KCNQ1 and KCNH2.
The technical expertise was established through
collaboration with the University Hospital of
Basel. If HCM is suspected, the genetic testing of
12 genes using resequencing technology is per-
formed in Geneva [41]. The results of the genetic
analyses, including a written interpretation, are
then transmitted to the investigating magistrate.
The forensic pathologist evaluates the results to
determine if the initial diagnosis must be modi-
fied, and subsequently encourages the family to
seek genetic counselling. If family members are
not contacted or decline to be informed, there is
no follow-up. Genetic counselling of family
members can occur at any step of the forensic in-
vestigation: at the beginning, after transmission of
the results of the molecular autopsy or at a later
undetermined date depending on the ability to
contact family members or their individual de-
sires. The basic flow chart is presented in figure 1.
Discussion
Over the past decade, genetic testing for car-
diac channelopathies and cardiomyopathies has
mostly been performed for the purpose of basic sci-
ence and to establish genotype–phenotype correla-
tions. There has been great insight into the diag-
nostic, prognostic, and therapeutic implications of
genetic testing. Postmortem genetic testing (mol-
ecular autopsy) has been carried out in some aca-
demic centres on cases without a morphological ex-
planation for the sudden death [1, 8, 42–46]. These
centres identified previously described pathogenic
mutations responsible for long QT syndrome and
catecholaminergic polymorphic ventricular tachy-
cardia. The molecular autopsies were also per-
formed on cases of sudden infant death syndrome
(SIDS); with results indicating that approximately
5–10% of SIDS are due to defective cardiac ion
channels [10, 46]. The present recommendation is
to perform genetic analyses on any case of SCD
with a negative autopsy [47–50].
Studies evaluating the first-degree relatives of
SCD victims have shown a high prevalence of ge-
netically determined cardiac pathologies [51–53].
In light of these findings, clinical guidelines state
that the investigation of any surviving relatives is
crucial in identifying affected individuals and in
attempts to decrease the risk of further sudden
death [4, 24, 49, 52].
Unfortunately, the link between the post-
mortem investigation of a SCD victim and the
clinical investigation of surviving family members
is difficult to establish in most countries. This dif-
ficulty may result from legal restrictions, such as
lack of consent of the victim or the next of kin, or
from the inability to contact the families. From an
ethical point of view, family members of SCD vic-
tims should have access to the results of the au-
topsy and genetic tests. The majority of genetic
heart diseases show an autosomal dominant inher-
itance pattern with marked clinical heterogeneity,
meaning that the probability of having additional
family members affected is high, but the variabil-
ity in presenting phenotypes is great. Clinical het-
erogeneity can render obtaining a clinical diagno-
sis more difficult. Incomplete penetrance and
variable expression are common in arrhythmic
syndromes, such as LQTS, Brugada syndrome
and CPVT, and consequently lead to concealed
forms of these disorders [54]. This being said, the
clinical assessment of surviving family members
alone may not allow for the detection of LQTS or
CPVT.
The difficulty in reaching a diagnosis under-
scores the importance of the interdisciplinary col-
laboration between forensic pathologists, geneti-
cists and cardiologists. The clinical screening of
family members is most effective if any existing
mutations of the deceased are found during post-
mortem genetic testing. In our opinion, genetic
counselling and clinical screening of surviving
family members should be performed in all cases
of SCD, because the clinical history and examina-
tion of relatives may reveal a diagnosis of an ion
channelopathy or cardiomyopathy that even au-
topsy failed to detect. The genetic testing of the
victim and genetic counselling of surviving family
members is also recommended in cases with a
morphological substrate found at autopsy or dur-
ing clinical investigation, such as hypertrophic
cardiomyopathy.
Another common problem is that the families
often only communicate with the police or with
the investigating magistrate. The pathologist,
however, is authorised to speak to the family with
permission from the judge. Unfortunately, classi-
cal police investigations of SCD cases are often
unable to properly uncover pertinent facts related
to the individuals’ medical history. Naturally, it is
of the utmost importance that the police or judges
direct their investigation to exclude any criminal
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activity. For this reason, significant clinical or
family history may not be reported to the forensic
pathologist. This important information could be
obtained during genetic counselling. Occasion-
ally, the results of the autopsy are not properly re-
layed to the family or are not transmitted with a
sufficient explanation. It is of primary importance
to improve the system of transmission of autopsy
results in cases of sudden cardiac death in order to
increase the percentage of families receiving ge-
netic counselling and cardiological assessment,
and to identify any asymptomatic carriers of car-
diac disease.
SCD cases raise many legal and ethical ques-
tions for the forensic pathologist and the general
practitioner. The forensic pathologist acts as an
expert and has no therapeutic relation with the
deceased and his family. It is, however, impossible
for forensic pathologists to ignore genetic dis-
eases among the causes for death. From an ethical
point of view, determining the cause of death for
forensic purposes should be separated from the
ethical issues of its implications for the family. An
autopsy diagnosis not only determines the cause
of sudden death, but may enable the detection of
any carriers among family members in order to
prevent any future ones. The general practition-
ers’ role is twofold: to demand an autopsy in all
cases of SCD, and to refer the family members to
a centre specialised in cardiac genetic counselling.
Although physicians are not legally bound to in-
form their patients of the genetic risks of disease,
from an ethical standpoint they should inform
family members that in a significant percentage of
sudden deaths (especially in children and young
adults) treatable genetic disorders can be identi-
fied. They should respect the family’s wish to
know or not to know, as expressed during the ge-
netic counselling.
Genetic testing can also be performed many
years after the death if the samples are properly
collected and stored. EDTA blood and a few
grams of cardiac or splenic tissues should be
stored at −80 °C, or alternatively stored in RNA
later [19, 20, 47]. At present our routine screening
concerns only a few genes: SCN5A, KCNQ1 and
KCNH2. Ryanodine receptor gene mutations re-
lated to CPVT are not currently included in rou-
tine molecular autopsy practice, although several
studies have suggested CPVT as the cause of
SCD in young adults, in SIDS, and in a case of
unexplained drowning [55, 56]. Further research
will certainly permit to uncover more genes im-
plicated in diseases resulting in sudden death and
technical advances will render testing more cost
effective. For this reason, appropriate sampling
and storage is crucial in the anticipation of future
technical progress in molecular biology and the
overall understanding of the genetic origin of
many diseases.
Conclusion
Independent of its cause, the death of a young
individual is tragic for those left behind. When
the death is sudden and unexplained, the grief is
much more inconsolable. The role of all impli-
cated medical practitioners should be revised in
order to make this tragedy easier for families, to
prevent additional deaths in surviving family
members, and in the interest of public health. A
thorough autopsy using the recent advances in
medicine and cardio genetics is essential for all in-
dividuals involved. International guidelines con-
cerning postmortem genetic testing and trans-
mission of the results to the family members
should be proposed for cases of SCD.Appropriate
handling of the case requires a multidisciplinary
collaboration, including the generalist who certi-
fies the death, the (forensic) pathologist perform-
ing the autopsy, the clinical geneticist and the car-
diologist who will evaluate the risk of sudden
death for family members. This article outlines an
ethical and modern approach to all cases of sud-
den cardiac death.
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